This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

This study has been terminated.
(DSMB recommendation due to lack of efficacy. There were no safety signals.)
Sponsor:
Information provided by (Responsible Party):
Merrimack Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01774851
First received: January 10, 2013
Last updated: June 19, 2017
Last verified: June 2017
Results First Received: May 10, 2017  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: HER-2 Gene Amplification
Esophagus Cancer
Gastroesophageal Junction Cancer
Stomach Cancer
Interventions: Drug: MM-111
Drug: Paclitaxel
Drug: Trastuzumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Control Group Paclitaxel + Trastuzumab
Experimental Group MM-111 + trastuzumab + paclitaxel

Participant Flow:   Overall Study
    Control Group   Experimental Group
STARTED   42   42 
COMPLETED   42   42 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Control Group Trastuzumab + paclitaxel
Experimental Group MM-111 + trastuzumab + paclitaxel
Total Total of all reporting groups

Baseline Measures
   Control Group   Experimental Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 42   42   84 
Age 
[Units: Years]
Median (Full Range)
 62.5 
 (35 to 81) 
 63.5 
 (31 to 78) 
 63 
 (31 to 81) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      2   4.8%      5  11.9%      7   8.3% 
Male      40  95.2%      37  88.1%      77  91.7% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      1   2.4%      1   2.4%      2   2.4% 
Not Hispanic or Latino      41  97.6%      41  97.6%      82  97.6% 
Unknown or Not Reported      0   0.0%      0   0.0%      0   0.0% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      0   0.0%      0   0.0%      0   0.0% 
Asian      12  28.6%      11  26.2%      23  27.4% 
Native Hawaiian or Other Pacific Islander      0   0.0%      0   0.0%      0   0.0% 
Black or African American      0   0.0%      2   4.8%      2   2.4% 
White      30  71.4%      29  69.0%      59  70.2% 
More than one race      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      0   0.0%      0   0.0%      0   0.0% 
Region of Enrollment 
[Units: Participants]
     
United States   13   13   26 
Denmark   0   1   1 
France   1   0   1 
Korea, Republic of   11   10   21 
Spain   9   8   17 
Taiwan   2   2   4 
United Kingdom   6   8   14 
Subject of child bearing potential 
[Units: Participants]
Count of Participants
 0   2   2 
Height 
[Units: Cm]
Median (Full Range)
 172 
 (154.2 to 190.5) 
 170.19 
 (152.4 to 193.0) 
 171 
 (152.4 to 193) 
Weight 
[Units: Kg]
Median (Full Range)
 73.97 
 (47.1 to 126.6) 
 68 
 (41.2 to 98.2) 
 72.51 
 (41.2 to 126.6) 


  Outcome Measures

1.  Primary:   Progression Free Survival (PFS)   [ Time Frame: 30 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Following the recommendation of the data monitoring committee, this study was terminated prior to enrollment being completed due to lack of efficacy.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: MM-111 Medical Director
Organization: Merrimack Pharmaceuticals
phone: 617-441-1000



Responsible Party: Merrimack Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01774851     History of Changes
Other Study ID Numbers: MM-111-13-02-04
Study First Received: January 10, 2013
Results First Received: May 10, 2017
Last Updated: June 19, 2017